CJC-1295 — Research Dossier
Evidence grading
Key study
2006
Teichman et al. — Phase 1/2 in healthy adults
GH increase (DAC)
2–10×
Sustained 6+ days after a single injection
IGF-1 increase (DAC)
1.5–3×
Lasting 9–11 days · half-life ~6–8 days
Approvals
0
Development did not advance beyond early trials
CJC-1295 is the rare growth-hormone secretagogue in this library with a published, controlled human trial — though that trial studied the long-acting DAC form, which differs from the short-acting "no-DAC" product commonly sold.
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). In its long-acting form it incorporates a Drug Affinity Complex (DAC) that binds serum albumin, extending its half-life to roughly 6–8 days and producing prolonged GH and IGF-1 elevation.
The widely sold "CJC-1295 without DAC" is a different, short-acting molecule — modified GRF(1-29) — with substantially less formal human study. The controlled human trial evidence described in this dossier applies to the DAC form only.
“A single injection produced dose-dependent increases in plasma GH of roughly two- to ten-fold sustained for six days or more, and IGF-1 increases of about 1.5- to three-fold lasting nine to eleven days.”
— Teichman SL et al., J Clin Endocrinol Metab 2006
The human evidence
The key study (Teichman et al., 2006) comprised two randomised, double-blind, placebo-controlled ascending-dose trials in healthy adults. A single injection of the DAC form produced dose-dependent increases in plasma GH of roughly two- to ten-fold sustained for six days or more, and IGF-1 increases of about 1.5- to three-fold lasting nine to eleven days, with an estimated half-life of around 6–8 days. The compound was reported as generally well tolerated at the studied doses.
Earlier animal work (Alba et al., 2006) showed once-daily CJC-1295 normalised growth in a GHRH-knockout mouse model. The molecular characterisation of the albumin-binding DAC mechanism was described by Jetté and colleagues (Endocrinology, 2005).
Clinical development did not advance beyond these early trials, and the compound holds no regulatory approval.
The DAC and no-DAC distinction
The controlled human evidence above describes the long-acting DAC form. The short-acting product labelled "CJC-1295 without DAC" — also sold as modified GRF(1-29) or Mod GRF(1-29) — is a different molecule. Without the albumin-binding modification, its half-life is measured in minutes rather than days, and the formal human pharmacology data from the Teichman trial do not extend to it.
The long-term safety of sustained GH and IGF-1 elevation — as would be produced by repeated DAC-form dosing — is not well characterised in the published literature.
What this evidence is — and isn’t
These trials studied pharmaceutical-grade CJC-1295 administered under medical supervision in controlled settings. The figures summarised in this dossier describe that published science only.
They are not outcomes associated with research-grade material, and not results attributable to any use of the product sold in this catalogue. Nothing here is an endorsement, recommendation, or instruction for human use.
Nexyra Lab Catalogue
This dossier covers published clinical research on CJC-1295. Nexyra Lab supplies research-grade CJC-1295 for in vitro laboratory use.
View CJC-1295 in the Nexyra catalogue (research use only) →See also
References
- 1
Teichman SL, Neale A, Lawrence B, et al. Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006.
- 2
Alba M, et al. Once-daily administration of CJC-1295 normalizes growth in the GHRH-knockout mouse. Am J Physiol Endocrinol Metab. 2006.
- 3
Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lived GRF analog. Endocrinology. 2005.
Research & Laboratory Use Only
This dossier is compiled for research planning and educational purposes only. It summarises published scientific literature and does not constitute medical advice, dosing guidance, or a therapeutic claim. All Nexyra Lab products are for research purposes only and are not for human or veterinary use. Nothing in this document should be interpreted as recommending, endorsing, or facilitating the self-administration of any compound.
A one-time legal review of this template and disclaimer is recommended before the Journal section is made publicly accessible, given the health-adjacent nature of this content.